Max A. Cayo, Sunil K. Mallanna, Francesca Di Furio, Ran Jing, Lauren B. Tolliver, Matthew Bures, Amanda Urick, Fallon K. Noto, Evanthia E. Pashos, Matthew D. Greseth, Maciej Czarnecki, Paula Traktman, Wenli Yang, Edward E. Morrisey, Markus Grompe, Daniel J. Rader, Stephen A. Duncan
Index: 10.1016/j.stem.2017.01.011
Full Text: HTML
Cayo et al. of the NHLBI NextGen consortium use hepatocytes from familial hypercholesterolemia iPSCs in a drug screen that highlights cardiac glycosides as a candidate treatment acting to reduce apoB levels via proteolytic turnover and as a result lower LDL-C.
|
ASCL1 Reorganizes Chromatin to Direct Neuronal Fate and Supp...
2017-07-13 [10.1016/j.stem.2017.06.004] |
|
Lineage Tracing: Papers and Progress
2017-07-06 [10.1016/j.stem.2017.06.015] |
|
Intestinal Enteroendocrine Lineage Cells Possess Homeostatic...
2017-07-06 [10.1016/j.stem.2017.06.014] |
|
Direct Neuronal Reprogramming: Achievements, Hurdles, and Ne...
2017-07-06 [10.1016/j.stem.2017.06.011] |
|
Making HSCs on Demand: Looking Ahead
2017-07-06 [10.1016/j.stem.2017.06.010] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2026 ChemSrc All Rights Reserved